Cover Image
Market Research Report

Biologics IP - A Strategic Review

Published by Frost & Sullivan Product code 370700
Published Content info 71 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biologics IP - A Strategic Review
Published: August 10, 2016 Content info: 71 Pages
Description

Profiling Patenting Activity of 13 Major Pharma-biotech Companies in the Area of Biologics

This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking. This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.

Table of Contents
Product Code: D6AE-01-00-00-00

Table of Contents

1 1.0 EXECUTIVE SUMMARY

  • 1.0 Executive Summary

2 2.0 RESEARCH OBJECTIVE AND BACKGROUND

  • 2.1 Research Objective
  • 2.2 Biologics versus Small Molecule
  • 2.3 Big Pharma Shifting Focus from Small Molecule to Biologics, Why?
  • 2.4 Big Pharma Gained Biologics Expertise through Mergers and Acquisitions (M&A)-Important Deals

3 3.0 RESEARCH SCOPE AND METHODOLOGY

  • 3.1 Research Scope and Concepts
  • 3.2 Analysis Approach
  • 3.3 Keywords and IPC Codes Used for Clustering by Biologics Type
  • 3.4 Therapeutic Areas Covered in the Study

4 4.0 BIOLOGICS PATENT PORTFOLIOS OF THE TOP 13 MAJOR PHARMA COMPANIES

  • 4.1 Competitive Benchmarking of the Top 13 Major Pharma Companies Based on Their Biologics Patent Portfolios, 1996-2015

5 5.0 OVERVIEW OF BIOLOGICS PATENT PORTFOLIO5.1 COMPANY 1: ROCHE

  • 5.1.1 Mapping of Roche's Patent Portfolio by Biologics Type
  • 5.1.2 Mapping of Roche's Patent Portfolio by Therapeutic Area

6 5.2 COMPANY 2: GSK

  • 5.2.1 Mapping of GSK's Patent Portfolio by Biologics Type
  • 5.2.2 Mapping of GSK's Patent Portfolio by Therapeutic Area

7 5.3 COMPANY 3: MERCK

  • 5.3.1 Mapping of Merck's Patent Portfolio by Biologics Type
  • 5.3.2 Mapping of Merck's Patent Portfolio by Therapeutic Area

8 5.4 COMPANY 4: SANOFI

  • 5.4.1 Mapping of Sanofi's Patent Portfolio by Biologics Type
  • 5.4.2 Mapping of Sanofi's Patent Portfolio by Therapeutic Area

9 5.5 COMPANY 5: NOVARTIS

  • 5.5.1 Mapping of Novartis's Patent Portfolio by Biologics Type
  • 5.5.2 Mapping of Novartis's Patent Portfolio by Therapeutic Area

10 5.6 COMPANY 6: BRISTOL-MYERS SQUIBB

  • 5.6.1 Mapping of Bristol-Meyers Squibb's Patent Portfolio by Biologics Type
  • 5.6.2 Mapping of Bristol-Meyers Squibb's Patent Portfolio by Therapeutic Area

11 5.7 COMPANY 7: AMGEN

  • 5.7.1 Mapping of Amgen's Patent Portfolio by Biologics Type
  • 5.7.2 Mapping of Amgen's Patent Portfolio by Therapeutic Area

12 5.8 COMPANY 8: NOVO NORDISK

  • 5.8.1 Mapping of Novo Nordisk's Patent Portfolio by Biologics Type
  • 5.8.2 Mapping of Novo Nordisk's Patent Portfolio by Therapeutic Area

13 5.9 COMPANY 9: PFIZER

  • 5.9.1 Mapping of Pfizer's Patent Portfolio by Biologics Type
  • 5.9.2 Mapping of Pfizer's Patent Portfolio by Therapeutic Area

14 5.10 COMPANY 10: ELI LILLY

  • 5.10.1 Mapping of Eli Lilly's Patent Portfolio by Biologics Type
  • 5.10.2 Mapping of Eli Lilly's Patent Portfolio by Therapeutic Area

15 5.11 COMPANY 11: ASTRAZENECA

  • 5.11.1 Mapping of AstraZeneca's Patent Portfolio by Biologics Type
  • 5.11.2 Mapping of AstraZeneca's Patent Portfolio by Therapeutic Area

16 5.12 COMPANY 12: BAYER HEALTHCARE

  • 5.12.1 Mapping of Bayer HealthCare's Patent Portfolio by Biologics Type
  • 5.12.2 Mapping of Bayer HealthCare's Patent Portfolio by Therapeutic Area

17 5.13 COMPANY 13: ABBVIE

  • 5.13.1 Mapping of AbbVie's Patent Portfolio by Biologics Type
  • 5.13.2 Mapping of AbbVie's Patent Portfolio by Therapeutic Area

18 6.0 KEY FINDINGS

  • 6.1 Key Findings
  • Legal Disclaimer

19 7.0 APPENDIX

  • 7.1 Acronyms

20 8.0 THE FROST & SULLIVAN STORY

  • 8.1 The Frost & Sullivan Story
  • 8.2 Value Proposition: Future of Your Company & Career
  • 8.3 Global Perspective
  • 8.4 Industry Convergence
  • 8.5 360° Research Perspective
  • 8.6 Implementation Excellence
  • 8.7 Our Blue Ocean Strategy
Back to Top